Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase NA 7Phase 3 6Phase 1 4Phase 2/3 3Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Glioblastoma 12Astrocytoma 11Glioma 10Brain Neoplasms 9Gliosarcoma 7Oligodendroglioma 6Central Nervous System Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 4Breast Neoplasms 4Meningioma 3Esophageal Neoplasms 3Colorectal Neoplasms 3Stomach Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Pinealoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Medulloblastoma 2Craniopharyngioma 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1

Interventions

Fluorouracil 38Capecitabine 31Oxaliplatin 30Leucovorin 30Radiotherapy 21Irinotecan 20Bevacizumab 15Radiation 12Cetuximab 12pembrolizumab 9Gemcitabine 7trifluridine tipiracil drug combination 5dehydroftorafur 5cediranib 5Radiotherapy, Intensity-Modulated 5Folfox protocol 5Erlotinib Hydrochloride 5Cisplatin 5Carboplatin 5trametinib 4Surgical Procedures, Operative 4Paclitaxel 4Neoadjuvant Therapy 4Gene Expression Profiling 4Cyclophosphamide 4sargramostim 3binimetinib 3Trifluridine 3Sorafenib 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Rectal Neoplasms × Surgical Procedures, Operative × Clear all
NCT04638036 2024-04-16

TRACT-II

University Medical Center Groningen

Phase 1 Completed
11 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02910843 2023-01-10

RECAP

Swiss Cancer Institute

Phase 1 Terminated
25 enrolled
Gastrointestinal

Rectal Neoplasms

NCT00543842 2015-02-26

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
19 enrolled
Gastrointestinal

Rectal Neoplasms

NCT00215956 2013-12-23

A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
31 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡